Regeneron Pharmaceuticals Inc (REGN) is around the top of the Biotechnology industry according to InvestorsObserver. REGN received an overall rating of 79, which means that it scores higher than 79 percent of all stocks. Regeneron Pharmaceuticals Inc also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 10 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Regeneron Pharmaceuticals Inc Stock Today?
Regeneron Pharmaceuticals Inc (REGN) stock is down -2.87% while the S&P 500 is unmoved 0% as of 10:38 AM on Tuesday, Apr 28. REGN is lower by -$15.74 from the previous closing price of $547.52 on volume of 430,590 shares. Over the past year the S&P 500 has fallen -2.19% while REGN is up 54.52%. REGN earned $18.46 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 28.81.
